secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001104659-24-037619
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline
--------------------------------------------------------------------------------

- Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.
- Tender offer resulted in 77.3% of shares tendered (93.7M shares); remaining shares converted at same price.
- CymaBay becomes wholly owned subsidiary; CBAY to be delisted from Nasdaq on March 22, 2024.
- Transaction expected to reduce Gilead's 2024 GAAP/non-GAAP EPS by $3.10-$3.20; including costs, $3.35-$3.45 relative to prior guidance.
- Seladelpar (for primary biliary cholangitis) is key asset; safety/efficacy not yet established.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/0001104659-24-037619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465924037619/tm249475d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer